We continually strive to be a reliable and valued partner in the financial markets. Debt capital investors are key to our financing strategy and success. For your convenience, we’ve provided below a variety of resources including our debt investor presentation as a summary overview, our key ratings and current bonds outstanding.
Our Debt Investor presentation streamlines our key credit-related data into one accessible document.
If you have any further questions related to debt capital, please do not hesitate to contact us.
Bonds Outstanding
Bayer refinances the business mainly through U.S. Dollar and Euro debt capital markets. Below you find a list of all currently outstanding bonds issued by Bayer Group entities. Please note that we cannot provide prospectuses for any of these securities for legal reasons.
Ratings from internationally recognized agencies allow lenders to assess the risk inherent in financial instruments as companies seek to raise funds in the capital markets by issuing bonds, commercial paper, or other debt instruments. These agencies have confirmed the following ratings, which allow us to access capital markets to issue bonds. With a proven track record of disciplined deleveraging, Bayer remains committed to meeting the “A” target category rating through the long-term.
Bayer launches jumbo bond issuance with a volume of USD 7 billion
Successful placement as part of the financing of the acquisition of the OTC business of Merck & Co., Inc., United States / Six tranches with maturities of two to ten years MORE
Investor News June 25, 2014
Not intended for U.S. Media - To finance the acquisition of the consumer care business of Merck & Co., Inc.
Bayer issues hybrid capital of EUR 3.25 billion
Largest corporate euro hybrid bond transaction worldwide MORE
Investor News January 21, 2014
Bayer issues EUR 2 billion of bonds
Transaction comprises two-year floating-rate tranche and two EUR 750 million fixed-rate bonds with maturities of four and seven years MORE
